Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PRKDC : new biomarker and drug target for checkpoint blockade immunotherapy

1 Mar 2020

Abstract excerpt

Background Immunological checkpoint blockade is effective in treating various malignancies. Identifying predictive biomarkers to assist patient selection for immunotherapy has become a priority in both clinical and research settings. Methods Mutations in patients who responded to immunotherapy were identified through next-generation sequencing. Relationships among protein kinase, DNA-activated, catalytic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Colorectal Cancer Treatments and Studies
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32238472
DOI: 10.1136/jitc-2019-000485

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PRKDC : new biomarker and drug target for checkpoint blockade immunotherapyPMID 32238472Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

Potential Value of PRKDC as a Therapeutic Target and Prognostic Biomarker in Pan-CancerSemantic proximity Read ↗

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.Semantic proximity Read ↗

CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment.Semantic proximity Read ↗

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsSemantic proximity Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

Pan-cancer landscape of protein kinase D3: An integrative TCGA multi-omics analysis of clinical, molecular, and immunological roles.Semantic proximity Read ↗

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.Semantic proximity Read ↗

Prognostic and potential therapeutic roles of PRKDC expression in lung cancerSemantic proximity Read ↗

Death associated protein kinase 1 predicts the prognosis and the immunotherapy response of various cancers.Semantic proximity Read ↗

[Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].Semantic proximity Read ↗

The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.